These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21819622)

  • 1. Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.
    Romero Q; Bendahl PO; Klintman M; Loman N; Ingvar C; Rydén L; Rose C; Grabau D; Borgquist S
    BMC Cancer; 2011 Aug; 11():341. PubMed ID: 21819622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.
    Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O
    Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of neoadjuvant therapy on breast cancer biomarker profile.
    Rey-Vargas L; Mejía-Henao JC; Sanabria-Salas MC; Serrano-Gomez SJ
    BMC Cancer; 2020 Jul; 20(1):675. PubMed ID: 32682413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.
    Knutsvik G; Stefansson IM; Aziz S; Arnes J; Eide J; Collett K; Akslen LA
    PLoS One; 2014; 9(11):e112121. PubMed ID: 25375149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer.
    Tokuda E; Horimoto Y; Arakawa A; Himuro T; Senuma K; Nakai K; Saito M
    Hum Pathol; 2017 May; 63():40-45. PubMed ID: 28237784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
    Robertson S; Rönnlund C; de Boniface J; Hartman J
    Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens.
    Ahn S; Lee J; Cho MS; Park S; Sung SH
    Arch Pathol Lab Med; 2018 Mar; 142(3):364-368. PubMed ID: 29144790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.
    Jones RL; Salter J; A'Hern R; Nerurkar A; Parton M; Reis-Filho JS; Smith IE; Dowsett M
    Breast Cancer Res Treat; 2009 Jul; 116(1):53-68. PubMed ID: 18592370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume.
    Focke CM; Decker T; van Diest PJ
    Ann Surg Oncol; 2017 May; 24(5):1251-1257. PubMed ID: 28008571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple digital image analysis system for automated Ki67 assessment in primary breast cancer.
    Alataki A; Zabaglo L; Tovey H; Dodson A; Dowsett M
    Histopathology; 2021 Aug; 79(2):200-209. PubMed ID: 33590538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.
    Iwamoto T; Katagiri T; Niikura N; Miyoshi Y; Kochi M; Nogami T; Shien T; Motoki T; Taira N; Omori M; Tokuda Y; Fujiwara T; Doihara H; Gyorffy B; Matsuoka J
    Oncotarget; 2017 Apr; 8(16):26122-26128. PubMed ID: 28412725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
    Acs B; Leung SCY; Kidwell KM; Arun I; Augulis R; Badve SS; Bai Y; Bane AL; Bartlett JMS; Bayani J; Bigras G; Blank A; Buikema H; Chang MC; Dietz RL; Dodson A; Fineberg S; Focke CM; Gao D; Gown AM; Gutierrez C; Hartman J; Kos Z; Lænkholm AV; Laurinavicius A; Levenson RM; Mahboubi-Ardakani R; Mastropasqua MG; Nofech-Mozes S; Osborne CK; Penault-Llorca FM; Piper T; Quintayo MA; Rau TT; Reinhard S; Robertson S; Salgado R; Sugie T; van der Vegt B; Viale G; Zabaglo LA; Hayes DF; Dowsett M; Nielsen TO; Rimm DL;
    Mod Pathol; 2022 Oct; 35(10):1362-1369. PubMed ID: 35729220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
    Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
    Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
    Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
    Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
    Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?
    Sueta A; Yamamoto Y; Hayashi M; Yamamoto S; Inao T; Ibusuki M; Murakami K; Iwase H
    Surgery; 2014 May; 155(5):927-35. PubMed ID: 24582496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
    Martin LA; Davies GL; Weigel MT; Betambeau N; Hills MJ; Salter J; Walsh G; A'Hern R; Dowsett M
    Breast Cancer Res Treat; 2010 Oct; 123(3):829-36. PubMed ID: 20697803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel model for Ki67 assessment in breast cancer.
    Romero Q; Bendahl PO; Fernö M; Grabau D; Borgquist S
    Diagn Pathol; 2014 Jun; 9():118. PubMed ID: 24934660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant therapy with celecoxib to women with early stage breast cancer.
    Tfayli A; Yang J; Kojouri K; Kesserwan C; Jafari M; Ozer H
    Neoplasma; 2008; 55(2):122-6. PubMed ID: 18237249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
    Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.